INSULIN GLARGINE 300U/ML AND INSULIN GLARGINE 100U/ML SHOW EQUIPOTENT IN VIVO BLOOD GLUCOSE LOWERING WHEN ADMINISTERED INTRAVENOUSLY IN DOGS

被引：0

作者：

Werner, U. ^{[1
]}

Korn, M. ^{[1
]}

Tennagels, N. ^{[1
]}

机构：

[1] Sanofi, Diabet Div, Frankfurt, Germany

来源：

DIABETES TECHNOLOGY & THERAPEUTICS | 2016年 / 18卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

296

引用

页码：A119 / A119

页数：1

共 50 条

[41] Use of Insulin Glargine 100U/mL for the Treatment of Type 2 Diabetes Mellitus in East Asians: A Review
Hirose, Takahisa
Chen, Ching-Chu
Ahn, Kyu Jeung
Kiljanski, Jacek
[J]. DIABETES THERAPY, 2019, 10 (03) : 805 - 833
[42] Plasma C-Peptide Concentration and Risk of Hypoglycemia in People with T2DM Treated with Insulin Glargine 300 U/mL (Gla-300) or Insulin Glargine 100 U/mL (Gla-100)
Bolli, Geremia
Ritzel, Robert
Yale, Jean-Francois
Escalada, Javier
Davies, Melanie
Landgraf, Wolfgang
Bertolini, Monica
Hecquet, Carole
Yki-Jarvinen, Hannele
Rosenstock, Julio
[J]. DIABETES, 2017, 66 : A258 - A258
[43] Improved real-world outcomes for type 2 diabetes patients on basal-bolus insulin therapy switching to insulin glargine 300 U/ml vs. insulin glargine 100 U/ml and insulin Detemir
Wu, Jasmanda
Bailey, Timothy S.
Bosnyak, Zsolt
Westerbacka, Jukka
Gupta, Rishab A.
Menon, Arjun A.
Nicholls, Charlie
Blonde, Lawrence
[J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 416 - 417
[44] Day-to-day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs
Miller, Michelle
Pires, Jully
Crakes, Katti
Greathouse, Rachel
Quach, Nina
Gilor, Chen
[J]. JOURNAL OF VETERINARY INTERNAL MEDICINE, 2021, 35 (05) : 2131 - 2139
[45] REAL-WORLD EVIDENCE DEMONSTRATES COMPARABLE CLINICAL OUTCOMES OF SWITCHING FROM INSULIN GLARGINE 100 U/ML TO INSULIN GLARGINE 300 U/ML VS INSULIN DEGLUDEC IN T2D PATIENTS
Blonde, L.
Zhou, F. L.
Bosnyak, Z.
Westerbacka, J.
Gupta, V. E.
Sharma, R. K.
Bailey, T. S.
[J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A137 - A138
[46] Real-World Health Outcomes in Patients with T2D Initiating Insulin Glargine 300 U/mL vs. Insulin Glargine 100 U/mL in a Specialist Endocrinology Practice
Abitbol, Alexander
Brown, Ruth E.
Jiandani, Dishay
Aronson, Ronnie
[J]. DIABETES, 2017, 66 : A272 - A272
[47] Lower pharmacokinetic and pharmacodynamic within-day variability of individual clinical doses of insulin glargine 300 U/ml vs glargine 100 U/ml in type 1 diabetes
Fanelli, C. G.
Lucidi, P.
Candeloro, P.
Cioli, P.
Andreoli, A. Marinelli
Bolli, G. B.
Porcellati, F.
[J]. DIABETOLOGIA, 2018, 61 : S409 - S409
[48] Comparative effectiveness of insulin glargine 300 U/mL and insulin degludec 100 U/mL in insulin naive type 2 diabetes adults: the Restore-2 naive cohort
Fadini, G. P.
Buzzetti, R.
Larosa, M.
Rossi, M. C.
Nicolucci, A.
Cucinotta, D.
[J]. DIABETOLOGIA, 2021, 64 (SUPPL 1) : 74 - 74
[49] New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1)
Matsuhisa, M.
Koyama, M.
Cheng, X.
Takahashi, Y.
Riddle, M. C.
Bolli, G. B.
Hirose, T.
[J]. DIABETES OBESITY & METABOLISM, 2016, 18 (04): : 375 - 383
[50] Efficacy and Safety of Switching from Insulin Glargine 100 U/mL to the Same Dose of Glargine 300 U/mL in Japanese Type 1 and 2 Diabetes Patients: A Retrospective Analysis
Nakanishi, Shuhei
Iwamoto, Masahiro
Kamei, Shinji
Hirukawa, Hidenori
Shimoda, Masashi
Tatsumi, Fuminori
Kohara, Kenji
Obata, Atsushi
Kimura, Tomohiko
Kinoshita, Tomoe
Irie, Shintaro
Sanada, Junpei
Fushimi, Yoshiro
Nishioka, Momoyo
Mizoguchi, Akiko
Kameyama, Miyuki
Mune, Tomoatsu
Kaku, Kohei
Kaneto, Hideaki
[J]. INTERNAL MEDICINE, 2018, 57 (10) : 1381 - 1389

← 1 2 3 4 5 →